NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Last trade$2.33
Day change+$0.18 (+8.37%)
Day range$2.10 – $2.46
Volume1,068,982
Market cap$94M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$93.84M
Price / earnings
—
Price / book
-552×
Price / sales
27.65×
EV / sales
19.91×
EV / EBITDA
-3.42×
Profitability
Earnings per share
-$0.54
Return on assets
-68.74%
Return on equity
13,811.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.42×
Current ratio
0.86×
Quick ratio
0.86×
Cash ratio
0.79×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.67M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NRXP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$1.1M
$1.07M
$983K
$242K
$0
$0
$0
$0
Cost of revenue
$675K
$631K
$408K
$97K
$0
$0
$0
$0
Gross profit
$426K
$437K
$575K
$145K
$0
$0
$0
$0
Selling, general and administrative
$4.75M
$3.81M
$4.57M
$2.81M
$2.74M
$2.94M
$2.6M
$2.41M
Research and development
$2.12M
$1.31M
$558K
$1.43M
$987K
$804K
$1.04M
$611K
Total operating expenses
$6.93M
$5.18M
$5.2M
$4.17M
$3.73M
$3.85M
$2.43M
$3.02M
Operating income
-$6.51M
-$4.74M
-$4.62M
-$4.02M
-$3.73M
-$3.85M
-$2.43M
-$3.02M
Interest expense
-$240K
-$233K
-$671K
$0
$0
$0
$0
$0
Income before taxes
-$16.52M
-$1.43M
$360K
-$5.89M
-$17.58M
-$5.51M
-$9.08M
-$1.62M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$16.52M
-$1.43M
$360K
-$5.89M
-$17.58M
-$5.51M
-$9.08M
-$1.62M
Net income attributable to common shareholders
-$16.52M
-$1.43M
$360K
-$5.89M
-$17.58M
-$5.51M
-$9.08M
-$1.62M
EBITDA
-$6.43M
-$4.69M
-$4.55M
-$4.09M
-$3.73M
-$3.75M
-$3.63M
-$3.02M
Basic earnings per share
-$0.44
-$0.04
$0.01
-$0.27
-$0.98
-$0.34
-$0.74
-$0.15
Diluted earnings per share
-$0.44
-$0.04
$0.01
-$0.27
-$0.98
-$0.34
-$0.74
-$0.15
Recent news
Company coverage with links to the original publishers.
NRx Pharmaceuticals reported a Q3 loss of $0.05 per share, beating expectations of $0.29 loss, but missed revenue estimates with $1.16 million versus consensus. The company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, and shares have underperformed the S&P 500 by 29.7% year-to-date.
NRx Pharmaceuticals commenced sales of its FDA-approved preservative-free ketamine this week through a 17-person veteran sales force covering approximately 80% of the U.S. market. The product uses blow-fill-seal (BFS) technology in a needle-free vial, addressing a ketamine shortage since 2018 and eliminating the controversial preservative benzethonium chloride. The company expects gross and net margins exceeding 50% and has contracted with German suppliers to expand manufacturing capacity in South Carolina.
Shionogi & Co. reported Q2 earnings of $0.08 per share, missing the consensus estimate of $0.13 and down from $0.18 year-ago. However, revenues of $1.18 billion exceeded estimates by 5.14%. The company maintains a Zacks Rank #2 (Buy) rating despite the earnings miss, with favorable estimate revision trends. The stock has underperformed the S&P 500 year-to-date, gaining 5% versus the market's 13.1%.
NRx Pharmaceuticals announced that its management team, led by CEO Jonathan Javitt, will participate in three investor conferences in September 2026: Moody Capital Solutions Disruptive Growth & Life Sciences Conference (Sept 9), Cantor Global Healthcare Conference (Sept 11), and H.C. Wainwright 28th Annual Global Investment Conference (Sept 14). The company is a clinical-stage biopharmaceutical firm developing NMDA platform therapeutics for CNS disorders including suicidal depression, chronic pain, and PTSD.
NRx Pharmaceuticals announced the pricing of an underwritten public offering of 5.7 million shares at $3.50 per share, expected to raise approximately $20 million (or $23 million with full underwriter option). The clinical-stage biopharmaceutical company plans to use net proceeds for working capital and general corporate purposes. The offering is expected to close on June 4, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.